Log In
BCIQ
Print this Print this
 

Xlucane, Biosimilar ranibizumab

  Manage Alerts
Collapse Summary General Information
Company Xbrane Biopharma AB
DescriptionBiosimilar of ranibizumab, a humanized mAb fragment against VEGF-A
Molecular Target Vascular endothelial growth factor A (VEGF-A)
Mechanism of ActionVascular endothelial growth factor A (VEGF-A) inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation
PartnerHelvetic BioPharma S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/15/2016

Undisclosed

0

Undisclosed

Get a free BioCentury trial today